PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PD PagerDuty, Inc.

劳工日休市 09-04 16:00:00 EDT

13.62

-0.48

-3.40%

盘后13.59

-0.03-0.25%

19:30 EDT

最高13.88	最低13.51	成交量159.38万
今开13.88	昨收14.10	日振幅2.62%
总市值10.71亿	流通市值9.62亿	总股本7,865万
成交额2,184万	换手率2.26%	流通股本7,064万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PD","market":"US","secType":"STK","nameCN":"PagerDuty, Inc.","latestPrice":13.62,"timestamp":1788552000000,"preClose":14.1,"halted":0,"volume":1593828,"hourTrading":{"tag":"盘后","latestPrice":13.5858,"preClose":13.62,"latestTime":"19:30 EDT","volume":98328,"amount":1339208.3382,"timestamp":1788564607295,"change":-0.0342,"changeRate":-0.002511,"amplitude":0.002511},"delay":0,"changeRate":-0.03404255319148939,"floatShares":70635553,"shares":78649873,"eps":2.03,"marketStatus":"劳工日休市","change":-0.48,"latestTime":"09-04 16:00:00 EDT","open":13.88,"high":13.88,"low":13.51,"amount":21843610.374672,"amplitude":0.026241,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.03,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1554955200000,"exchange":"NYSE","adjPreClose":14.1,"preHourTrading":{"tag":"盘前","latestPrice":14,"preClose":14.1,"latestTime":"08:46 EDT","volume":52,"amount":728.49998,"timestamp":1788525982571,"change":-0.1,"changeRate":-0.007092,"amplitude":0.007092},"postHourTrading":{"tag":"盘后","latestPrice":13.5858,"preClose":13.62,"latestTime":"19:30 EDT","volume":98328,"amount":1339208.3382,"timestamp":1788564607295,"change":-0.0342,"changeRate":-0.002511,"amplitude":0.002511},"volumeRatio":0.6816149466273219,"impliedVol":0.6682,"impliedVolPercentile":0.3849},"requestUrl":"/m/hq/s/PD/wiki","defaultTab":"wiki","newsList":[{"id":"2664842856","title":"康方生物(09926.HK)：依沃西对比帕博利珠用于一线治疗PD -L1表达阳性NSCLC的HARMONi-2研究期中分析达到OS关键次要终点 具有统计学显著和临床获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664842856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664842856?lang=zh_cn&edition=full","pubTime":"2026-09-03 07:11","pubTimestamp":1788390684,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PD","BK4023","LU1169589451.USD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178051887","title":"PagerDuty宣布裁员约15%——SEC文件披露重组细节","url":"https://stock-news.laohu8.com/highlight/detail?id=1178051887","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178051887?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:48","pubTimestamp":1787863709,"startTime":"0","endTime":"0","summary":"8月27日（路透社）——PagerDuty, Inc.今日向美国证券交易委员会提交的文件中宣布，公司将进行约15%的员工人数削减。根据文件内容，PagerDuty预计此次裁员将产生550万美元至750万美元的非经常性费用。通过精简组织结构，PagerDuty旨在提升运营效率并重新聚焦核心业务领域。文件同时指出，此次重组涉及的具体部门及员工影响范围尚未完全披露，但公司承诺将按相关法规要求履行对受影响员工的责任和义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169590202.USD","LU1169589451.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162660383","title":"PagerDuty预计裁员相关非经常性费用在550万至750万美元之间——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1162660383","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162660383?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:08","pubTimestamp":1787861293,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.在最新提交的SEC文件中透露，公司预计与裁员计划相关的非经常性费用将在550万至750万美元区间内。值得注意的是，这一费用预估反映了PagerDuty在优化运营效率方面的积极举措，同时也暗示了公司正面临需要重新配置资源的经营环境。具体的费用构成和裁员规模等详细情况，在该SEC文件中均有进一步说明。PagerDuty作为一家提供数字运营管理平台的技术公司，其人员调整决策往往被视为行业风向标之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1169590202.USD","LU1169589451.USD","PD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119927725","title":"PagerDuty披露重组计划：2027财年第三季度计提重组费用，第四季度末完成裁员","url":"https://stock-news.laohu8.com/highlight/detail?id=1119927725","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119927725?lang=zh_cn&edition=full","pubTime":"2026-08-28 04:08","pubTimestamp":1787861291,"startTime":"0","endTime":"0","summary":"PagerDuty, Inc.向美国证券交易委员会提交的文件显示，该公司预计将在2027财年第三季度确认重组相关费用，并计划于2027财年第四季度末完成人员精简工作。与此同时，PagerDuty的裁员计划也有明确时间表——所有涉及的人员缩减将在2027财年第四季度末前画上句号。这一举措表明公司正积极重塑组织架构，以应对当前市场环境下的业务需求。此次重组计划的细节通过官方SEC文件对外公布，为投资者和市场观察者提供了关于公司未来走向的明确信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","LU1169589451.USD","BK4023","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662105790","title":"惠正奇医药创始人回爱民：mRNA癌症疫苗大规模应用仍需3-5年，不会取代CAR-T或PD-1/PD-L1疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2662105790","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662105790?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:30","pubTimestamp":1787740212,"startTime":"0","endTime":"0","summary":"如果后续获得监管批准，它将成为全球首个上市的mRNA肿瘤疫苗，开启个体化肿瘤疫苗治疗的新时代。回爱民：我认为，mRNA个性化癌症疫苗不会简单取代CAR-T或PD-1/PD-L1疗法，而是会带来差异化竞争和新的联合模式。因此，mRNA疫苗对PD-1/PD-L1疗法的影响主要是协同增效。intismeran取得阳性结果的方案本身就是与帕博利珠单抗联合，说明个性化疫苗未来更可能扩大PD-1/PD-L1疗法的获益人群，而不是取代它。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1787738561624097620","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1169590202.USD","159938","BK1574","BK4023","PD","CAR","BK1161","159646","09939","BK4230","BK1515","BK4022","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662192769","title":"挑战PD-L1“药王”成功，康方生物的PD-1双抗擂台赛从肺癌打到了胆道癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2662192769","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662192769?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:33","pubTimestamp":1787708009,"startTime":"0","endTime":"0","summary":"继头对头挑战默沙东K药物后，康方生物（09926.HK)的PD-1/VEGF双抗依沃西擂台赛还在继续。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854239539.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854239539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","LU2476274308.USD","PD","LU0348825331.USD","LU0348783233.USD","LU0348827113.USD","LU0540923850.HKD","BK1574","LU0561508036.HKD","IE00BPRC5H50.USD","LU0417516571.SGD","LU1169589451.USD","LU0348766576.USD","LU1794554557.SGD","LU0417516902.SGD","LU2399975544.HKD","09926","LU2488822045.USD","IE00B5MMRT66.SGD","LU0348767384.USD","LU0634319403.HKD","LU0348735423.USD","LU0348784397.USD","LU1961090484.USD","IE00B543WZ88.USD","LU2778985437.USD","LU2476274720.SGD","LU1169590202.USD","BK1161","LU0417516738.SGD","LU1720050803.USD","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662020178","title":"维立志博-B(09887)：维利信®(奥帕替苏米单抗，PD-L1/4-1BB双特异性抗体，LBL-024)一线治疗ESCC的Ⅱ期临床研究进入扩展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2662020178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662020178?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:56","pubTimestamp":1787612198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B 发布公告，本公司自主研发的在研药物维利信一线治疗局部晚期或转移性食管鳞癌的Ⅱ期临床研究，已完成安全性导入期并在观察到的积极疗效信号及良好的安全性和耐受性基础上，顺利进入扩展阶段。截至目前，维利信一线治疗肺外神经内分泌癌、小细胞肺癌及胆道癌的三项POC研究已全部完成患者入组，其中一线EP-NEC已进入确证性III期临床阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1169589451.USD","BK1161","HK0000500386.USD","HK0000252160.HKD","09887","PD","BK4023","LU1169590202.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970199","title":"康方生物(09926)：依达方®(依沃西，PD-1/VEGF)第三个适应症上市申请获得国家药品监督管理局批准，用于一线治疗SQ-NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970199","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658970199?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:01","pubTimestamp":1786539717,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，由公司自主研发的全球首创双特异性抗体依达方联合化疗用于一线治疗晚期鳞状非小细胞肺癌的新药上市申请，已获得中国国家药品监督管理局批准上市。这是依沃西获批上市的第三个适应症。依沃西联合化疗一线治疗sq-NSCLC新适应症的获批上市，是基于依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期sq-NSCLC的随机、对照、多中心III期临床研究中获得的显著阳性结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1720050803.USD","KURE","BK1574","LU0348784397.USD","BK4023","LU1169589451.USD","LU2488822045.USD","LU0348767384.USD","LU2778985437.USD","LU0348827113.USD","LU0540923850.HKD","LU2399975544.HKD","LU2476274308.USD","IPOS","LU0348825331.USD","PD","LU2476274720.SGD","BK1161","LU0417516571.SGD","09926","LU0561508036.HKD","LU1169590202.USD","IE00B543WZ88.USD","LU0348783233.USD","LU0417516902.SGD","LU0634319403.HKD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU1961090484.USD","IE00BPRC5H50.USD","LU0348766576.USD","LU1794554557.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657904156","title":"把肿瘤变成“原位疫苗”!Replimune(REPL.US)溶瘤病毒闯过FDA，PD-1耐药黑色素瘤迎来新一代免疫重启方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2657904156","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657904156?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:59","pubTimestamp":1786085956,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4023","PD","LU1169589451.USD","BK4585","LU1169590202.USD","BK4588","REPL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655490356","title":"复宏汉霖(02696)：注射用HLX43(靶向PD-L1抗体偶联药物)联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655490356","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655490356?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:33","pubTimestamp":1785486809,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复宏汉霖 发布公告，近日，注射用HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤治疗的临床试验申请获国家药品监督管理局批准。HLX43是由本公司利用许可引进的新型DNA拓扑异构酶I抑制剂小分子毒素-肽链连接子与本公司自主研发的靶向PD-L1的抗体进行偶联开发的靶向PD-L1的抗体偶联药物，拟用于晚期/转移性实体瘤的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000306701.USD","IBBJ","PD","BK4023","BK1161","LU1169589451.USD","HK0000165453.HKD","MDTX","HK0000320223.HKD","BMED","IBBQ","LU1169590202.USD","PSYK","HK0000306685.HKD","02696","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652298475","title":"无问芯穹夏立雪：随着跨集群异构PD分离架构规模化落地，推理成本仍有10倍下降空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2652298475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652298475?lang=zh_cn&edition=full","pubTime":"2026-07-20 15:21","pubTimestamp":1784532097,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1169589451.USD","BK4023","PD","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652638792","title":"基石药业-B(02616)：ESMO 2026预告-更多临床数据进一步验证 CS2009(PD-1/VEGF/CTLA-4三特异性抗体)临床潜力与全球开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2652638792","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652638792?lang=zh_cn&edition=full","pubTime":"2026-07-20 08:06","pubTimestamp":1784505987,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B(02616)发布公告，公司核心资产之一CS2009(PD-1/VEGF/CTLA-4三特异性抗体)的临床研究成果成功入选2026年欧洲肿瘤内科学会(ESMO)年会，并将以两项快速口头报告的形式呈现，分别涵盖CS2009在晚期非小细胞肺癌(NSCLC)以及转移性结直肠癌(mCRC)患者中的I/II期临床试验数据。目前，相关摘要标题已在ESMO官网公布。需说明的是，摘要中所呈现的数据仅截至2026年4月，旨在符合大会递交期限之要求。基石药业将于2026年10月23日至26日在西班牙马德里召开的ESMO年会现场，展示数据截止日期更临近会议时间的临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1169590202.USD","BK4023","PD","02616","LU1169589451.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651348206","title":"科伦博泰生物(06990)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)联合帕博利珠单抗一线治疗PD-L1阴性局部晚期或转移性非鳞状非小细胞肺癌3期临床研究达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2651348206","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651348206?lang=zh_cn&edition=full","pubTime":"2026-07-15 07:32","pubTimestamp":1784071939,"startTime":"0","endTime":"0","summary":"安全性方面，芦康沙妥珠单抗联合帕博利珠单抗的安全性特征与既往研究报告一致，未观察到新的安全性信号。目前，本公司已在中国开展9项注册性临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","PD","LU1169590202.USD","LU1169589451.USD","LU0196878994.USD","06990","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651104260","title":"安捷伦PD-L1伴随诊断试剂获FDA批准，用于食管胃癌免疫治疗筛选","url":"https://stock-news.laohu8.com/highlight/detail?id=2651104260","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651104260?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:38","pubTimestamp":1784039880,"startTime":"0","endTime":"0","summary":"安捷伦科技公司近日宣布，其PD-L1 IHC 28-8 pharmDx试剂盒已获得美国食品药品监督管理局的批准，可作为伴随诊断工具，用于识别可能适合接受免疫治疗的患者。该试剂盒现可正式用于评估食管鳞状细胞癌、胃癌、胃食管交界处癌及食管腺癌患者的PD-L1蛋白表达水平。　　安捷伦表示，此次获批有助于标准化相关癌症的免疫治疗患者筛选流程，支持全球临床医生做出更精准的治疗决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-14/doc-inihuxfu8357115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1169589451.USD","PD","BK4023","BK4588","LU1169590202.USD","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650907155","title":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","url":"https://stock-news.laohu8.com/highlight/detail?id=2650907155","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650907155?lang=zh_cn&edition=full","pubTime":"2026-07-10 14:43","pubTimestamp":1783665784,"startTime":"0","endTime":"0","summary":"恒瑞医药回应PD-1联合疗法在美延迟批准：未涉及产品临床研究数据问题","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103801735795.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801735795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0188","LU2488822045.USD","LU1255011170.USD","LU1820825898.SGD","01276","BK1191","LU1328615791.USD","BK0028","LU1997245094.SGD","LU2097828805.USD","LU0359202008.SGD","LU1064131003.USD","LU0359201612.USD","LU2097828631.EUR","LU1655091616.SGD","BK0239","LU0405327494.USD","BK0183","LU1781817850.SGD","LU1997245177.USD","BK0012","LU2097828714.EUR","LU2289578879.USD","LU2580892789.USD","PD","LU0405327148.USD","LU1169590202.USD","LU2495084118.USD","LU0359201885.HKD","BK4023","LU1146622755.USD","LU2148510915.USD","BK0196","LU2543165471.USD","LU1169589451.USD","LU2580892862.HKD","BK0060","LU1969619763.USD","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","LU1064130708.USD","LU1023057109.AUD","LU1580142542.USD","LU1997244956.HKD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648220025","title":"和誉-B(02256)附属与阿斯利康达成战略合作开展同类首创口服PD-L1抑制剂ABSK043联合泰瑞沙®治疗非小细胞肺癌的临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2648220025","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648220025?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:06","pubTimestamp":1782950774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，本公司的附属公司上海和誉生物医药科技有限公司宣布，与阿斯利康签署战略合作协议，共同推进一项新型靶免联合疗法治疗非小细胞肺癌的临床研究。该联合研究是一项多中心、开放的I/II期临床试验，旨在评估和誉医药自主研发的同类首创口服小分子PD-L1抑制剂 ABSK043联合阿斯利康第三代EGFR-TKI泰瑞沙 ，用于治疗EGFR突变合并PD-L1阳性的局部晚期或转移性NSCLC患者中的安全性和疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2089984988.USD","LU2237443895.HKD","AZNH","LU2778985437.USD","LU2476274720.SGD","LU2237443978.SGD","BK4568","LU0289739699.SGD","IE00BPRC5H50.USD","LU2237443382.USD","LU0432979614.USD","LU1267930573.SGD","LU2237443465.HKD","LU2462157665.USD","LU1169589451.USD","BK4007","IE00B5MMRT66.SGD","BK4585","BK1161","PD","LU2468319806.SGD","LU0058720904.USD","LU1169590202.USD","LU0320765992.SGD","LU1829250122.USD","LU0708994859.HKD","LU0889565916.HKD","BK4588","02256","LU2236285917.USD","LU2488822045.USD","IE00B3T34201.USD","BK4023","LU2417539215.USD","LU0109394709.USD","IE00B543WZ88.USD","LU0310800379.SGD","AZN","LU2476274308.USD","LU0029864427.USD","LU0128525929.USD","LU2237443549.SGD","LU2237443622.USD","LU2456880835.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642293703","title":"先声药业(02096)：SIM0689(PD-1/VEGF双特异性抗体)获国家药品监督管理局签发药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2642293703","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642293703?lang=zh_cn&edition=full","pubTime":"2026-06-12 21:02","pubTimestamp":1781269339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，先声药业(02096)发布公告，集团自主研发的靶向PD-1/ VEGF的双特异性抗体SIM0689已获得中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书，拟开展晚期实体瘤的临床试验。SIM0689是一种同时靶向程序性死亡受体1(PD-1)和血管内皮生长因子(VEGF)特殊表位的双特异性抗体，通过解除肿瘤细胞免疫抑制和抗血管生成，发挥强效的抗肿瘤活性。在多种人源化小鼠药效模型中，SIM0689在低剂量即展现出优异的抗肿瘤疗效，整体药效显著优于同类型分子，提示其在多种实体瘤中有广泛的应用前景。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4023","LU1169589451.USD","PD","LU1169590202.USD","02096","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642407722","title":"西南证券：PD~(L)1经治后耐药困局不容忽视 2026年催化密集","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407722","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642407722?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:52","pubTimestamp":1781164329,"startTime":"0","endTime":"0","summary":"目前康方生物AK104联合普络西单抗(VEGFR2单抗)，取得了目前IO经治肺癌已披露研究数据中最长的OS，mOS=16.7mo。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260611/20260611152451_49256.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0183","BK0028","BK4107","LU1169589451.USD","BK0012","L","BK0276","LU0053666078.USD","LU2487616109.SGD","PD","LU1169590202.USD","BK4585","BK4588","BK4023","LU0210528500.USD","600369","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640437984","title":"港股异动 | 康方生物(09926)高开逾9% 依沃西联合化疗战胜PD-1联合化疗OS结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2640437984","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640437984?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:24","pubTimestamp":1780277063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物今日大幅高开，截至发稿，涨9.23%，报129港元，成交额3.62亿港元。消息面上，康方生物PD-1/VEGF双抗依沃西单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的III期HARMONi-6研究于ASCO大会全体会议公布最新结果。与替雷利珠单抗联合化疗相比，依沃西组患者死亡风险下降34%，OS达到统计学显著性，两年生存率64.7% vs 48.6%。HARMONi-6共入组532例患者，中央型鳞癌占比约63%，PD-L1 TPS＜1%患者占39%，多部位转移、肝转移及脑转移患者占比约33.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448269.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","BK1161","LU0348783233.USD","LU0348825331.USD","IE00B5MMRT66.SGD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0634319403.HKD","BK1574","LU1794554557.SGD","09926","LU1961090484.USD","IE00B543WZ88.USD","LU0348735423.USD","LU2778985437.USD","BK4585","LU0348784397.USD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD","LU0348827113.USD","BK4588","LU0561508036.HKD","VXUS","BK4023","LU1169590202.USD","LU0417516738.SGD","LU2476274308.USD","LU0348767384.USD","LU1169589451.USD","PD","LU0417516902.SGD","LU2476274720.SGD","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639136988","title":"中国创新药迎高光！康方生物核心产品战胜PD-1联合化疗总生存期结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2639136988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639136988?lang=zh_cn&edition=full","pubTime":"2026-05-31 21:16","pubTimestamp":1780233368,"startTime":"0","endTime":"0","summary":"5月31日，《每日经济新闻》记者注意到，在2026年美国临床肿瘤学会（ASCO）年会上，康方生物（HK09926，股价118.10港元，市值1088亿港元）PD-1/VEGF双抗依沃西联合化疗对比替雷利珠单抗联合化疗，一线治疗晚期鳞状非小细胞肺癌（sq-NSCLC）III期HARMONi-6/AK112-306研究的OS（总生存期）显著阳性结果揭晓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605313755214061.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605313755214061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0417516571.SGD","LU0417516902.SGD","LU0561508036.HKD","LU0348784397.USD","LU1169590202.USD","BK1161","LU0634319403.HKD","LU0348827113.USD","LU1169589451.USD","PD","IE00BPRC5H50.USD","06978","BK4023","LU0348825331.USD","LU0417516738.SGD","LU2476274308.USD","LU1794554557.SGD","LU0348767384.USD","BK1574","159992","LU1720050803.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0348766576.USD","LU1961090484.USD","LU2399975544.HKD","LU2778985437.USD","LU0348783233.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","09926","LU2488822045.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pagerduty.com","stockEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":0.2139},{"period":"3month","weight":0.4724},{"period":"6month","weight":0.7068},{"period":"1year","weight":-0.178},{"period":"ytd","weight":0.0389}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"PagerDuty, Inc.于2010年5月根据特拉华州法律成立。该公司及其全资子公司提供了一个数字运营管理平台，为现代数字业务管理紧急和关键任务工作（“PagerDuty平台”）。PagerDuty平台从几乎任何支持软件的系统或设备收集数据和数字信号，并利用先进的人工智能和强大的机器学习实时关联、处理、预测和补救事件和机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.011871},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.075547},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.032883},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.032585},{"month":5,"riseRate":0.375,"avgChangeRate":0.055631},{"month":6,"riseRate":0.625,"avgChangeRate":0.015298},{"month":7,"riseRate":0.625,"avgChangeRate":0.027655},{"month":8,"riseRate":0.625,"avgChangeRate":0.041604},{"month":9,"riseRate":0,"avgChangeRate":-0.104519},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.036422},{"month":11,"riseRate":0.571429,"avgChangeRate":0.021164},{"month":12,"riseRate":0.571429,"avgChangeRate":0.042574}],"exchange":"NYSE","name":"PagerDuty, Inc.","nameEN":"PagerDuty, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"PagerDuty, Inc.,PD,PagerDuty, Inc.股票,PagerDuty, Inc.股票老虎,PagerDuty, Inc.股票老虎国际,PagerDuty, Inc.行情,PagerDuty, Inc.股票行情,PagerDuty, Inc.股价,PagerDuty, Inc.股市,PagerDuty, Inc.股票价格,PagerDuty, Inc.股票交易,PagerDuty, Inc.股票购买,PagerDuty, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"PagerDuty, Inc.(PD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供PagerDuty, Inc.(PD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}